CureVac said it could mass-produce a COVID-19 immunisation from its existing facilities if its low-dose approach turns out to be successful in clinical testing, as reported in This is Money.
The company, which is among the vaccine developers funded by the Coalition for Epidemic Preparedness Innovations, hopes to have an experimental vaccine ready by June or July to then seek regulatory clearance for testing on humans.
Florian von der Muelbe, chief production officer, explained that a mode of action that allowed for a low dosage to trigger an immune reaction against rabies would also be applied in the coronavirus setting.
"These minimal dosages that we have achieved put us in a position here in Tuebingen [Germany] to produce up to 10 million doses per (production) campaign," said von der Muelbe of a potential coronavirus vaccine.
"We started with a multitude of (coronavirus vaccine) candidates and we're now selecting the two best out of them. Those will go into clinical trials," von der Muelbe added.
To read more NewsPoints articles, click here.